SCHEMBL4749048

SCHEMBL4749048

O=C(C(=O)c1ccncc1Cl)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.56
CES1 P23141 1/20 0.56
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
NPC1 O15118 2/20 0.45
POLB P06746 1/20 0.45
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
KCNE1 P15382 1/20 0.42
KCNQ1 P51787 1/20 0.42
EPHX2 P34913 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
P2RX1 P51575 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
KIF11 P52732 1/20 0.40
GPBAR1 Q8TDU6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5199342 0.81 CES2 (0.79) CES2CES1ALDH1A1TLR7KIF11
SCHEMBL9259850 0.78 JAK2 (0.50) CES2CES1JAK2JAK1TYK2
SCHEMBL1665446 0.77 JAK2 (0.67) JAK2JAK1TYK2NPC1KCNQ3
SCHEMBL4691580 0.77 PIK3CA (0.52) JAK2JAK1TYK2HIF1AEPAS1
SCHEMBL3172262 0.75 CES2 (1.00) CES2CES1EPHX2SRD5A2TRPV1
SCHEMBL14523451 0.74 PTPN1 (0.46) CES2CES1JAK2JAK1TYK2
SCHEMBL2080891 0.72 KDM4E (0.51) CES2CES1EPHX2ALDH1A1MAPT
SCHEMBL1666240 0.71 DHODH (0.50) JAK2JAK1TYK2EPHX2MAPT
SCHEMBL5184941 0.70 SMN1; SMN2 (0.65) CES2CES1JAK2JAK1TYK2
SCHEMBL1027417 0.70 TMPRSS4 (0.56) JAK2JAK1TYK2MAPTP2RX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1871762-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2008-01-02 EP disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed
WO-2006113704-A2 SUBTITUTED HETEROARYL CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 CES2 67/4885CES1 185/4885JAK2 2223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.